MTIM
CRDF icon

Marathon Trading Investment Management’s Cardiff Oncology CRDF Stock Holding History

Marathon Trading Investment Management’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-17,580
Closed -$39K – 288
2024
Q2 		$39K Buy
17,580
+2,580
+17% +$9.72K ﹤0.01% 258
2024
Q1 		$80.1K Buy
+15,000
New +$39.9K 0.01% 302

Other funds holding CRDF

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Marathon Trading Investment Management's CRDF Position: Q3 2024 in Review

Marathon Trading Investment Management sold out of Cardiff Oncology (CRDF) in Q3 2024, closing a stake of 17,580 shares — an estimated $39K sold.

Marathon Trading Investment Management first reported a position in CRDF in Q1 2024 and held it in 2 quarters. The position peaked at $80.1K in Q1 2024. 83 funds tracked by Wall St. Rank hold CRDF as of Q3 2024.

  • Marathon Trading Investment Management reported no remaining Cardiff Oncology position as of Q3 2024 after selling out during the quarter.
  • Marathon Trading Investment Management sold 17,580 Cardiff Oncology shares in Q3 2024, an estimated $39K.
  • Marathon Trading Investment Management first reported a position in Cardiff Oncology in Q1 2024 and held it in 2 quarters.
  • Marathon Trading Investment Management's Cardiff Oncology position peaked at $80.1K in Q1 2024.
  • 83 funds tracked by Wall St. Rank held Cardiff Oncology as of Q3 2024.

Based on Marathon Trading Investment Management's 13F filing for Q3 2024, filed 7 Nov 2024.